E2F1 and breast cancer: In this dataset, KIFC1 showed a 1.95-fold upregulation (p = 5.36 × 10−41), AURKB showed a 2.35-fold upregulation (p = 1.36 × 10−48), BIRC5 showed a 1.97-fold upregulation (p = 1.41 × 10−42), CDCA8 showed a 2.23-fold upregulation (p = 5.11× 10−55), ATAD2 showed a 1.63-fold upregulation (p = 6.23 × 10−23), E2F1 showed a 1.77-fold upregulation (p = 2.55 × 10−32), and FOXM1 showed a 2.37-fold upregulation (p = 1.95 × 10−45), in TP53-mutant versus TP53-wild-type breast cancers.